The closing session of Cancer Progress 2025 brought the year’s themes into sharp focus: oncology innovation is no longer defined solely by scientific breakthroughs — it’s shaped by whether those breakthroughs can be executed, scaled, and accessed in real-world care.
Across the pharma ecosystem, selectivity has replaced momentum. Evidence expectations now extend far beyond approval, and delivery constraints often surface earlier than ever. Advanced modalities are stress-testing manufacturing, access, and infrastructure, while patient inclusion is shifting upstream — influencing trial design and access strategy from day one.
This capstone recap explores:
- Where progress is being enabled — and where constraints are emerging
- How prioritization has become a defining capability
- Why commercialization readiness is now part of development strategy
- Signals of adaptation that point toward a more aligned, realistic future
Whether you’re a patient, sponsor, policymaker, clinician, investor, or innovator, these insights will help you navigate a more selective, more disciplined, and more interconnected oncology landscape.
Download the full recap to see what’s changing, what it demands of the field — and how those questions are already shaping Cancer Progress 2026.
Download Full Recap
"*" indicates required fields
